Organogenesis (NASDAQ:ORGO) Shares Gap Up – What’s Next?

Organogenesis Holdings Inc. (NASDAQ:ORGO) gapped up prior to trading on Tuesday . The stock had previously closed at $5.42, but opened at $5.56. Organogenesis shares last traded at $5.20, with a volume of 239,503 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upped their target price on shares of Organogenesis from $4.00 to $6.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 5th.

Organogenesis Trading Down 10.0 %

The company has a market cap of $596.09 million, a price-to-earnings ratio of -78.33 and a beta of 1.66. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. The business’s 50-day simple moving average is $4.16 and its 200-day simple moving average is $3.56.

Insider Buying and Selling

In related news, Director Michael Joseph Driscoll sold 25,000 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total transaction of $127,500.00. Following the sale, the director now owns 166,879 shares of the company’s stock, valued at $851,082.90. This trade represents a 13.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 36.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Organogenesis by 5.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 471,240 shares of the company’s stock valued at $1,348,000 after buying an additional 24,878 shares during the last quarter. Intech Investment Management LLC purchased a new stake in Organogenesis in the 3rd quarter worth approximately $43,000. Charles Schwab Investment Management Inc. raised its holdings in Organogenesis by 2.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 948,451 shares of the company’s stock valued at $2,713,000 after acquiring an additional 23,675 shares during the last quarter. FMR LLC lifted its stake in shares of Organogenesis by 34.2% during the 3rd quarter. FMR LLC now owns 173,595 shares of the company’s stock worth $496,000 after purchasing an additional 44,199 shares during the period. Finally, Captrust Financial Advisors acquired a new stake in shares of Organogenesis during the third quarter worth $36,000. 49.57% of the stock is currently owned by hedge funds and other institutional investors.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.